Milestone Pharmaceuticals stock gets Nasdaq compliance deadline
Published on 10/30/2026 at 01:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNasdaq-Frist setzt Milestone unter Druck
- Milestone Pharmaceuticals erhielt eine Mitteilung wegen eines Verstoßes gegen die Nasdaq-Regel zum Mindestgebot.
- Die bestehende Notierung an der Nasdaq Global Select Market ist laut Mitteilung zunächst nicht beeinträchtigt.
- Das Unternehmen prüft als mögliche Optionen einen Wechsel an den Nasdaq Capital Market oder einen Reverse Split.
Milestone Pharmaceuticals faces a Nasdaq compliance deadline after its common shares remained below the exchange's minimum bid-price requirement for 30 consecutive business days. The company received the Nasdaq notice on October 23, 2026, according to the SEC filing reproduced by StockTitan, which was filed on October 28.
Compliance window runs into 2027
The notice concerns Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of 1.00 US dollars for continued listing on the Nasdaq Global Select Market. Milestone has 180 calendar days, through April 21, 2027, to regain compliance.
To satisfy the requirement, the company's minimum bid price must close at or above 1.00 US dollars for at least 10 consecutive business days. The notice does not immediately affect Milestone's listing on the Nasdaq Global Select Market.
Possible routes remain conditional
If the company does not regain compliance during the initial period, it may be eligible to seek additional time by applying to transfer to the Nasdaq Capital Market. That route would require an application, a 5,000 US dollar fee and compliance with other initial-listing standards, including requirements related to publicly held shares.
Milestone also said it may consider a reverse stock split if necessary. Neither a transfer nor a reverse split has been announced as a completed corporate action. The filing states that Nasdaq staff would assess whether the company could cure the deficiency during a possible second compliance period.
Investor context
The notice adds a regulatory execution issue to the risk profile of the Canadian biotechnology company, while leaving the current Nasdaq listing in place for now. Investors will likely focus on the share-price recovery required during the compliance window and on any further corporate action the company may disclose.
Milestone Pharmaceuticals overview
- Company: Milestone Pharmaceuticals Inc.
- Ticker: MIST
- Listing: Nasdaq Global Select Market
- Event date: October 23, 2026
- Filing date: October 28, 2026
- Sector: Healthcare
- Industry: Biotechnology
The broader Canadian equity market provides the relevant regional backdrop for the company, as represented by the S&P/TSX Composite.
